Losartan therapy for cardiac disease in paediatricMarfan syndrome.
A case of severe early-onset Marfan syndrome (MFS) led us to ask the question: 'Should an ARB, particularly losartan [intervention], compared with beta blockade alone [comparison], be commenced in all paediatric MFS patients [patient] with aortic root dilatation [outcome]?' The current literature was critically appraised to address this question.
Clinical Genetics, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Lisa J
LJ
Ewans
Paediatric Cardiology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Phillip
P
Roberts
Clinical Genetics, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Lesley
L
Adès
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001011:Aorta / Q000002:abnormalities; D004108:Dilatation, Pathologic; D005260:Female; D006330:Heart Defects, Congenital / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D019808:Losartan / Q000627:therapeutic use*; D008382:Marfan Syndrome / Q000188:drug therapy*
D047228:Angiotensin II Type 1 Receptor Blockers; D019808:Losartan
cardiology; genetics; pharmacology